TAmiRNA: MicroRNA biomarker discovery data for Osteporosis released in the Journal of Bone and Mineral Research (JBMR)

Together with collaboration partners from University of California San Francisco (UCSF), TAmiRNA has successfully published the results of its biomarker discovery project in postmenopausal and  diabetic osteoporosis.

In this clinical study levels of 384 microRNAs were measured in serum from 40 postmenopausal women with a history of one or more fragility fractures and 40 healthy control subjects.

Novel data  normalization  protocols  were  established  and  machine  learning  algorithms  were  used  to identify  combinations  of  microRNAs  (“signatures”), which  were  able  to  accurately  classify osteoporotic  patients from controls. The best signatures contained 4 microRNAs and achieved classification  rates  with  area-under-the-curve  (AUC)  vales  >  0.95.  Cross-validation  and permutation controls were applied to control for overfitting of classification models.

Four  microRNAs  were  selected  for  functional  characterization:  miR-550a-5p,  miR-188-3p,  and miR-382-3p. All three miRNAs were shown to potentially impact osteogenic differentiation. These  data  provide  proof  that  serum  microRNAs  could  be  valuable  biomarkers  to  manage osteoporosis in type-2 diabetics and postmenopausal women. Potential applications of microRNA biomarkers include risk stratification, treatment selection and treatment monitoring. New data from validation studies will be presented during ASBMR 2016 in Atlanta.

More information: www.ncbi.nlm.nih.gov/pubmed/27345526


TAmiRNA  GmbH  is  a  biopharmaceutical  R&D  company  founded  to  drive  the  discovery  and development  of  microRNAs  (miRNAs)  as  tools  for  diagnosis  and  treatment  of  age-associated disorders  such  as  Osteoporosis,  Cardiovascular  Disease  and  Neurodegenerative  Disease. TAmiRNA targets to improve patient stability and quality of life with increasing age, by providing solutions for early risk assessment of disease and combined therapeutic treatment solutions.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.